Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioVaxys Technology's share price for the quarter that ended in Jul. 2024 was €0.04. BioVaxys Technology's Shares Outstanding (EOP) for the quarter that ended in Jul. 2024 was 241.91 Mil. Therefore, BioVaxys Technology's market cap for the quarter that ended in Jul. 2024 was €9.68 Mil.
BioVaxys Technology's quarterly market cap
increased
from Jan. 2024 (€4.65 Mil) to Apr. 2024 (€8.75 Mil) and
increased
from Apr. 2024 (€8.75 Mil) to Jul. 2024 (€9.68 Mil).
BioVaxys Technology's annual market cap
declined
from Oct. 2021 (€25.26 Mil) to Oct. 2022 (€13.04 Mil) and
declined
from Oct. 2022 (€13.04 Mil) to Oct. 2023 (€1.31 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioVaxys Technology's Enterprise Value for Today is €10.28 Mil.
BioVaxys Technology Market Cap Historical Data
The historical data trend for BioVaxys Technology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioVaxys Technology's Market Cap
For the Biotechnology subindustry, BioVaxys Technology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVaxys Technology's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Market Cap distribution charts can be found below:
* The bar in red indicates where BioVaxys Technology's Market Cap falls into.
BioVaxys Technology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioVaxys Technology's Market Cap for the fiscal year that ended in Oct. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVaxys Technology (FRA:5LB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioVaxys Technology Market Cap Related Terms
Thank you for viewing the detailed overview of BioVaxys Technology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:5LB has been successfully added to your 